Shaping better lives, one story at a time

Hetero enters into a voluntary licensing agreement with MSD for the manufacturing and distribution of ‘Molnupiravir’, an investigational Oral Therapeutic for the treatment of Covid-19.

Another potential drug to strengthen our fight against the pandemic.

In line with the continuous commitment towards the global fight against the ongoing pandemic, Hetero entered into a non-exclusive voluntary licensing agreement with MSD to enable access of Molnupiravir for Covid-19 treatment. Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorization by local regulatory agencies.

Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed Covid-19.

After launching critical drugs like Covifor (Remdesivir), Favivir including the patient compliant pack (Favipiravir) at crucial junctures, this agreement with MSD will further strengthen our country’s fight against Covid-19 with the launch of this potential drug.

Affirming our commitment to holistic responsibility on a global level!

Hetero pledges its support to the 10 Principles of United Nation’s Global Compact initiative

Hetero is an organization with true understanding and regard for corporate responsibility. It made conscious efforts over the years to build a value system centered on the aspects of transparency, public accountability, sustainability, human rights, and anti-corruption among others which define a responsible organization.

We have reaffirmed our commitment to the same on a global stage by pledging the support to 10 Principles of United Nation’s Global Compact initiative which calls on organizations and businesses across the world to act on them for securing a better future for all the people on this planet.

Also, by joining a league of organizations which truly care for people & processes, Hetero will now have the access to engage with collaborative projects of United Nations and work towards its broader development goals while benefitting from the resources & learnings by the virtue of this association.

The advantages in a nutshell:

• The UNGC provides a universal language for corporate responsibility and provides a framework to guide all businesses regardless of size, complexity or location.
• UNGC will guide every step of the way and will help the Company commit to, assess, define, implement, measure and communicate sustainability strategy, the Company can make a difference across four core areas: human rights, labour, the environment and anti-corruption.
• Unprecedented networking access with UNGC participants – representing nearly every industry sector and size, in over 160 countries.
• Access to partnerships with a range of stakeholders – to share best practices and emerging solutions.
• Best practice guidance – built on 15 years of successes.
• Tools, resources and trainings and Local Network support in 85 countries.
• The moral authority, knowledge and experience of the United Nations.

Yet another significant stride for Hetero in the battle against Covid-19

Hetero roped in as the manufacturing partner of RDIF for producing Sputnik V vaccine in India.

Hetero, through its biologics arm ‘Hetero Biopharma’ has been roped in as the manufacturing partner by the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), for producing Sputnik V - the world’s first registered vaccine against the novel coronavirus infection – in India.

As per the agreement, Hetero will be manufacturing over 100 million doses of the vaccine per year, upon the success of the presently ongoing clinical trials in the country. The vaccine ‘Sputnik V’ will be manufactured in our state-of-the-art single-use Biologics facility ‘Hetero Biopharma’ at Jadcherla, Hyderabad, India.

After launching critical drugs like Covifor (Remdesivir), Favivir including the patient compliant pack (Favipiravir) at crucial junctures to enable country’s fight against COVID-19, this agreement with RDIF comes across as yet another significant stride for Hetero. This development also showcases Hetero’s spirit of collaboration and penchant for contributing to global health and well-being.

This collaboration is another step towards our commitment in the battle against Covid-19 and realizing the objective of ‘Make-in-India’ campaign as envisioned by our Hon’ble Prime Minister of India.

Hetero’s fight against the pandemic has led to great milestones.

1,00,000 + patients treated, 8,00,000 vials supplied & a prestigious award in recognition and more...

Hetero's group company Hetero Healthcare has been honoured with the “Covid-19 drug launch excellence award” by Express Pharma for its contribution to providing access to Covifor (Remdesivir) to more than 1,00,000 patients during the most critical Covid-19 phase afflicting the country. Express Pharma Excellence Awards is one of the most prestigious awards that recognize the exceptional contribution of pharmaceutical companies to industry advancements in various domains. This year's award annual program was conducted on the 20th of August on E-platform. Heal Health Connect Solution, the most renowned marketing solution organization, in association with the Indian Express Group publications - Express Pharma, presented the Excellence Awards across several categories to a select few pharmaceutical companies for their outstanding contribution to the country in helping it meet the challenges during Covid-19.

This award is a significant achievement for all the employees of the entire Hetero Group across the supply chain. We thank each Hetero Group employee for their valuable contribution by ensuring an adequate supply of Covifor not only in India but around the world.